Phase II Studies in Soft Tissue Sarcoma: Time for Reappraisal

A phase II study with sorafenib in patients with angiosarcoma conducted by the French Sarcoma Group, and published in this issue of The Oncologist, is evaluated. The importance of proper design and conduct of phase II trials is stressed.

Saved in:
Bibliographic Details
Published inThe oncologist (Dayton, Ohio) Vol. 17; no. 2; pp. 154 - 156
Main Author Sleijfer, Stefan
Format Journal Article
LanguageEnglish
Published Durham, NC, USA AlphaMed Press 2012
Subjects
Antineoplastic Agents - therapeutic use
Benzenesulfonates - therapeutic use
Commentaries
Female
Hemangiosarcoma - drug therapy
Humans
Male
Niacinamide - analogs & derivatives
Phenylurea Compounds
Pyridines - therapeutic use
Online AccessGet full text

Cover

More Information
Summary:A phase II study with sorafenib in patients with angiosarcoma conducted by the French Sarcoma Group, and published in this issue of The Oncologist, is evaluated. The importance of proper design and conduct of phase II trials is stressed.
Bibliography:None.
Disclosures: Stefan Sleijfer
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
Disclosures: Stefan Sleijfer: None.
ISSN:1083-7159
1549-490X
DOI:10.1634/theoncologist.2011-0382